Cite
HARVARD Citation
Fleischmann, R. et al. (2009). Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Annals of the rheumatic diseases. 68 (6), pp. 805-811. [Online].